Infex Therapeutics acquires, develops and licenses innovative drugs to treat pandemic infections
Alderley Park
Joined July 2016
- Tweets1.6K
- Following1.7K
- Followers2.7K
- Likes1K
Pinned Tweet
Infex Therapeutics presents new Phase IIa data for RESP-X at ERS Congress 2026, providing further evidence on exploratory efficacy endpoints supporting progression to later stage development:
infextx.com/infex-therapeuti…
Infex Therapeutics to present new RESP-X Phase IIa data in late-breaking session at ERS Congress 2026:
infextx.com/infex-therapeuti…
Ahead of today's Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB) 27th public meeting, Infex Therapeutics @INFEX_TX has provided a written submission to the Council.
You can read our letter in full here:
infextx.com/infex-therapeuti…
Infex will be attending the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB) 27th Public Meeting on June 16, 2026.
See here for more information: health.gov/advisory-committe…
Our COO, Ian Cooper, and Research Leader, James Kirkham, will be attending the 5th SCI / RSC Symposium on Anti-Infectives Drug Discovery on Tuesday, 2nd June.
Find out more here: soci.org/events/fine-chemica…
Infex Therapeutics announces positive Phase IIa results for RESP-X in non-cystic fibrosis bronchiectasis patients colonised with Pseudomonas aeruginosa:
infextx.com/infex-therapeuti…
Infex Therapeutics secures £4.3 million funding to advance anti-infective pipeline targeting drug-resistant infections:
infextx.com/infex-therapeuti…
Infex's Head of Biology, Dr Nicki Ooi, was pleased to present our latest abstract poster "The antimicrobial susceptibility of a global panel of MBL-producing Enterobacterales" at ESCMID last week.
#AMR #ESCMIDGlobal2026
We're pleased to attend the One Health Summit today in Lyon, to explore the need for an integrated approach between human, animal, and environmental health, to solve critical health challenges such as antimicrobial resistance.
Our head of Business Development, Carl Curran, is looking forward to attending the One Health Economic Forum in Lyon next month.
If you are attending the Forum and want to meet Carl to learn more about Infex, drop us a message!
#AntimicrobialResistance #OneHealth
@AllianceBEAM
A great day attending #BioInfect 2026 at @AlderleyPark !
Infex's Chief Clinical Officer, Colm Leonard, delivered an update on our flagship RESP-X program, a Phase 2a monoclonal antibody to treat non-cystic fibrosis bronchiectasis (NCFB).
INFEX Therapeutics retweeted
#SpeakerWeek at #BioInfect closes with our final presenter, Chief Clinical Officer & Chair at
@INFEX_TX, Colm Leonard. He is a leading global expert on #AMR and was clinical lead for the UK #Antimicrobial Novel Value Assessment & Reimbursement Project.
bionow.glueup.com/event/bioi…
We are exhibiting at BioInfect 2026 on Thursday, 5th Feb at The Apiary, Alderley Park. Come and visit our stand.
The presentations will feature a keynote update from Colm Leonard, Chief Clinical Officer for Infex @LeonardColm
bionow.glueup.com/event/bion…
@Bionow
What a year 2025 has been for Infex Therapeutics!
We’ve made exciting progress advancing our innovative pipeline of first-in-class infectious disease programmes.
Some key achievements this year include:
🔬Awarded a £1 million PACE grant with Justus-Liebig-University Giessen awarded to develop a first-in-class antimicrobial for multi-drug-resistant bacteria
We look forward to an exciting 2026.
#InfectiousDiseases #AMR #Biotech #GlobalHealth #Innovation #Partnerships #YearInReview #2025Recap
This week is World AMR Awareness Week #WAAW We reflect on the growing antimicrobial resistance (AMR) pandemic, and what needs to be done to address this ongoing, growing, and urgent threat to global health🧵
This rising tide of treatment-resistant bacteria and fungi highlights the urgent need for new and novel therapeutics to break the resistance of these pathogens.
Find out more about Infex Therapeutics, and our work to combat antimicrobial resistance: infextx.com/